Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

6 results about "Anti cd19" patented technology

CD19 / CD38 multispecific antibodies

Provided herein are common light chain bispecific antibodies that bind CD38 and CD19. The common light chain bispecific antibodies comprise an anti-CD38 heavy chain variable region and anti CD19 heavy chain variable region that each have a negatively-charged amino acid at a terminal heavy chain variable region position. The common light chain bispecific antibodies comprise further comprise an anti-CD38 heavy chain constant region and anti-CD19 heavy chain constant region that each lack a C-terminal lysine residue. Further provided are nucleic acids encoding such common light chain bispecific antibodies and host cells comprising the nucleic acids. Also provided are methods of making such common light chain bispecific antibodies.
Owner:BIOGRAPH 55 INC

Novel bispecific anti CD19-CD20 car-t constructs and uses thereof

The present disclosure provides CD19 / CD20-binding domains and chimeric antigen receptors (CARs) based on the same, as well as corresponding nucleic acid molecules, vectors, cells, compositions, methods and uses, e.g., for the prevention and / or treatment of cancer and / or autoimmune disease.
Owner:LAKEFRONT BIOTHERAPEUTICS NV

Combination of anti CD19 antibody with BCL-2 inhibitor and uses thereof

To provide the use of a CD19-specific antibody in the production of pharmaceuticals for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and / or acute lymphoblastic leukemia, and a pharmaceutical combination for the treatment.SOLUTION: The present invention provides the use of a CD19-specific antibody, comprising HCDR1-HCDR3 regions comprising specific sequences and LCDR1-LCDR3 regions comprising specific sequences, in the production of pharmaceuticals for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and / or acute lymphoblastic leukemia, where the CD19-specific antibody is used in combination with a BCL-2 inhibitor.SELECTED DRAWING: Figure 1
Owner:MORFOZIS AG

Design and composition of huAnti-CD19 chimeric antigen receptor targeting b-cell malignancies thereof

The present invention provides to develop novel chimeric antigen receptor (CAR) encoded by an open reading frame 3 (ORF3) mRNA and amino acid sequences of any one of SEQ ID NO: 1 to SEQ ID NO: 109 specific to CD19 against hematologic malignancies associated with expression of Cluster of Differentiation 19 (CD19). The invention relates to the design of a synthetic CAR mRNA sequence comprising hu anti CD19 scFv, a hinge, a Transmembrane domain, a co-stimulatory domain and a CD3ζ signaling domain, where with the costimulatory is CD27 or 41BB for targeting and destroying malignant B-cells. This disclosure features anti-CD19 CAR T-cell therapy for antigen binding domains, directed to B cell malignancies, described herein.
Owner:LYSINE BIOTECH PTE LTD